All In Biotech

Drug Trial Radar · NCT02129673

A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension

A Phase 1/2 Multicenter, Randomized, Controlled Dose-Finding Study to Evaluate the Safety and Ocular Hypotensive Efficacy of 3 Dose Levels of the VS101 Subconjunctival Latanoprost Insert for 3 Months in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Last checked: Nov 19, 2026Latest source record: Mar 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

77

Actual

Start

May 2014

Primary completion

May 2017

Study completion Aug 2017

Sponsor

Lead sponsor
ViSci Ltd.Industry
Sponsor type
Industry
First posted
May 2, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Slow release formulation of latanoprost is compared for safety and pressure-lowering efficacy with topically administration of commercially available latanoprost in patient with glaucoma and ocular hypertension

Conditions

  • Open Angle Glaucoma
  • Ocular Hypertension

Interventions

  • VS101 Insert Dose ADrug

    Sustained release of latanoprost into the eye

  • VS101 Insert Dose BDrug

    Sustained release of latanoprost into the eye

  • VS101 Insert Dose CDrug

    Sustained release of latanoprost into the eye

  • Latanoprost 0.005% eye dropsDrug

    Latanoprost 0.005% eye drops administered once daily on the eye

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intra-ocular pressureTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Speciality Eyecare Centre

    Bellevue, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.